Scopus BioPharma Inc. (NASDAQ:SCPS) Relative Strength Index (RSI) is 49.70, with weekly volatility at 61.73% and ATR at 1.40. The SCPS stock’s 52-week price range has touched low of $5.13 and a $47.86 high. Intraday shares traded counted 0.86 million, which was -7.39% lower than its 30-day average trading volume of 801.68K. Its shares traded lower over the last trading session, losing -10.72% on 05/28/21. The shares fell to a low of $7.00 before closing at $7.08. SCPS’s previous close was $7.93 while the outstanding shares total 15.34M.
Investors have identified the Biotechnology company Scopus BioPharma Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $124.68 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Is the stock of SCPS attractive?
In related news, Vice Chairman, Gibson Robert J bought 150 shares of the company’s stock in a transaction that recorded on Feb 25. The purchase was performed at an average price of 9.29, for a total value of 1,393. As the purchase deal closes, the Executive Committee Chairman, Greenspan Ira Scott now bought 800 shares of the company’s stock, valued at 7,208. Also, Executive Committee Chairman, Greenspan Ira Scott bought 300 shares of the company’s stock in a deal that was recorded on Feb 24. The shares were cost at an average price of 9.45 per share, with a total market value of 2,835. Following this completion of disposal, the Executive Committee Chairman, Greenspan Ira Scott now holds 115 shares of the company’s stock, valued at 1,090. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.50%.